Objective: The goal of this study is to analyze the dormant microbiome present in blood of Parkinson’s disease (PD) patient and healthy controls samples by identifying and quantifying their bacterial microbiota through Next Generation Sequencing (NGS).

Background: Previous studies have suggested that dysbiosis of the intestinal microbiota can be related to several neurodegenarative diseases, including PD, however the exact mechanism of the gut and brain axis as well as alterations in the dormant microbiota present in blood of PD patients were not yet discovered. In this study we analyzed the microbiota present in whole blood of patients with PD between 50 and 65 years old from distinct clinical groups (tremulant, rigid akinetic and classic) and in early, moderate and advanced stage of disease, according to Hoehn & Yahr (H/Y) scale. We compared these data with healthy control group at the same age.

Method: The 58 samples and 19 healthy control group were analyzed by using Ion 16S™ Metagenomics Kit (Thermo Fisher) with Ion Torrent PGM Next Generation Sequencing-NGS platform in order to amplify and identify the hypervariable regions V2-4-8 and V3-6, 7-9 of the gene encoding the 16S ribosomal RNA of bacteria. Data analysis were performed by Ion Reporter. The results confirmation was performed by Real Time PCR (qPCR) using Quant Studio 12k (Thermo Fisher).

Results: A total of 32 bacterial genus was identified in healthy control group and PD patients. However, from these 32 genera, 20 of them were found in heathy control group blood microbiome whereas all the 32 genera were present in blood microbiome of PD’s patients. There were 20 genera found in each of them and 1 exclusive genus in tremulant group (Roseomonas); 7 exclusive genera in rigid aknetic group (Erwinia, Hafnia, Paenibacillus, Pantoea, Rahnella, Rickettsia and Xanthomonas); 3 exclusive genera in classic group (Methylobacterium, Sphingomonas and Veillonella) and 1 exclusive genera in healthy control group (Lautropia).

Conclusion: Our data showed that specific microbiota present in blood are associated to PD patients and their different clinical groups. The exclusiveness of microbiome present in each clinical group and the lack of them in heathy control group can suggest different profiles of the disease and also putative biomarkers for each clinical stage. Further analysis should be conducted in order to reveal the role of the altered PD microbiome.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/blood-metagenomics-analyses-of-brazilian-parkinsons-disease-patients-a-clinical-substype-study/